
Pliant Therapeutics, Inc.
NASDAQ:PLRX
1.86 (USD) • At close September 5, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|---|
Revenue
| 0 | 1.58 | 9.685 | 7.572 | 41.817 | 57.052 | 0 | 0 |
Cost of Revenue
| 2.125 | 0 | 3.681 | 3.204 | 0 | 0 | 0.666 | 0 |
Gross Profit
| -2.125 | 1.58 | 9.685 | 7.572 | 41.817 | 57.052 | -0.666 | 0 |
Gross Profit Ratio
| 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
Reseach & Development Expenses
| 169.31 | 127.797 | 96.936 | 77.549 | 66.193 | 47.353 | 24.415 | 14.526 |
General & Administrative Expenses
| 59.055 | 57.928 | 39.949 | 27.558 | 17.269 | 10.93 | 6.5 | 3.823 |
Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 59.055 | 57.928 | 39.949 | 27.558 | 17.269 | 10.93 | 6.5 | 3.823 |
Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | -0.049 | 0 |
Operating Expenses
| 228.365 | 185.725 | 136.885 | 105.107 | 83.462 | 58.283 | 30.915 | 18.349 |
Operating Income
| -228.365 | -184.145 | -127.2 | -97.535 | -41.645 | -1.231 | -30.915 | -18.349 |
Operating Income Ratio
| 0 | -116.547 | -13.134 | -12.881 | -0.996 | -0.022 | 0 | 0 |
Total Other Income Expenses Net
| 18.061 | 22.809 | 3.879 | 0.272 | 0.112 | 0.6 | 0.639 | 0.016 |
Income Before Tax
| -210.304 | -161.336 | -123.321 | -97.263 | -41.533 | -0.631 | -30.276 | -18.333 |
Income Before Tax Ratio
| 0 | -102.111 | -12.733 | -12.845 | -0.993 | -0.011 | 0 | 0 |
Income Tax Expense
| 0 | 0 | 0 | 0 | 0 | -0.816 | 0 | 0 |
Net Income
| -210.304 | -161.336 | -123.321 | -97.263 | -41.533 | -0.631 | -30.276 | -20.622 |
Net Income Ratio
| 0 | -102.111 | -12.733 | -12.845 | -0.993 | -0.011 | 0 | 0 |
EPS
| -3.47 | -2.75 | -2.94 | -2.71 | -1.17 | 0.005 | -1.83 | -25.67 |
EPS Diluted
| -3.47 | -2.75 | -2.94 | -2.71 | -1.17 | 0.005 | -1.83 | -25.67 |
EBITDA
| -228.365 | -158.228 | -118.849 | -95.728 | -40.335 | -0.118 | -30.249 | -18.057 |
EBITDA Ratio
| 0 | -100.144 | -12.271 | -12.642 | -0.965 | -0.002 | 0 | 0 |